Cargando…

Antibody Therapies for Large B-Cell Lymphoma

Large B-cell lymphomas (LBCLs) constitute a subgroup of aggressive but highly curable lymphoproliferative diseases. Treatment of relapsed/refractory (R/R) patients still represents an unmet clinical need, and novel drugs and combinations are in continuous development. The pan–B cell panel of surface...

Descripción completa

Detalles Bibliográficos
Autores principales: Novo, Mattia, Santambrogio, Elisa, Frascione, Pio Manlio Mirko, Rota-Scalabrini, Delia, Vitolo, Umberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141264/
https://www.ncbi.nlm.nih.gov/pubmed/34040344
http://dx.doi.org/10.2147/BTT.S281618
_version_ 1783696329760833536
author Novo, Mattia
Santambrogio, Elisa
Frascione, Pio Manlio Mirko
Rota-Scalabrini, Delia
Vitolo, Umberto
author_facet Novo, Mattia
Santambrogio, Elisa
Frascione, Pio Manlio Mirko
Rota-Scalabrini, Delia
Vitolo, Umberto
author_sort Novo, Mattia
collection PubMed
description Large B-cell lymphomas (LBCLs) constitute a subgroup of aggressive but highly curable lymphoproliferative diseases. Treatment of relapsed/refractory (R/R) patients still represents an unmet clinical need, and novel drugs and combinations are in continuous development. The pan–B cell panel of surface antigens that characterizes LBCL leads to a large umbrella of druggable targets. Monoclonal antibodies (mAbs) express their activity against lymphoma by targeting multiple tumor-specific antigens. This category consists of a number of molecules with different mechanisms of action, including naked mAbs, radioimmunoconjugates, antibody-drug conjugates, checkpoint inhibitors, and bispecific antibodies. In the last decade, apart from the well-known role of the anti-CD20 mAb rituximab, novel mAbs have led to remarkable steps forward in the treatment of R/R LBCL in monotherapy and combined with chemotherapy. Multiple studies are in development trying to bring these novel compounds into the frontline setting to empower the RCHOP effect or as alternative chemotherapy-free options for elderly/unfit patients. This review provides insight into antilymphoma mAbs, focused on the efficacy and safety of the main molecules approved or in development for LBCL andperspectives on the treatment of this disease.
format Online
Article
Text
id pubmed-8141264
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81412642021-05-25 Antibody Therapies for Large B-Cell Lymphoma Novo, Mattia Santambrogio, Elisa Frascione, Pio Manlio Mirko Rota-Scalabrini, Delia Vitolo, Umberto Biologics Review Large B-cell lymphomas (LBCLs) constitute a subgroup of aggressive but highly curable lymphoproliferative diseases. Treatment of relapsed/refractory (R/R) patients still represents an unmet clinical need, and novel drugs and combinations are in continuous development. The pan–B cell panel of surface antigens that characterizes LBCL leads to a large umbrella of druggable targets. Monoclonal antibodies (mAbs) express their activity against lymphoma by targeting multiple tumor-specific antigens. This category consists of a number of molecules with different mechanisms of action, including naked mAbs, radioimmunoconjugates, antibody-drug conjugates, checkpoint inhibitors, and bispecific antibodies. In the last decade, apart from the well-known role of the anti-CD20 mAb rituximab, novel mAbs have led to remarkable steps forward in the treatment of R/R LBCL in monotherapy and combined with chemotherapy. Multiple studies are in development trying to bring these novel compounds into the frontline setting to empower the RCHOP effect or as alternative chemotherapy-free options for elderly/unfit patients. This review provides insight into antilymphoma mAbs, focused on the efficacy and safety of the main molecules approved or in development for LBCL andperspectives on the treatment of this disease. Dove 2021-05-18 /pmc/articles/PMC8141264/ /pubmed/34040344 http://dx.doi.org/10.2147/BTT.S281618 Text en © 2021 Novo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Novo, Mattia
Santambrogio, Elisa
Frascione, Pio Manlio Mirko
Rota-Scalabrini, Delia
Vitolo, Umberto
Antibody Therapies for Large B-Cell Lymphoma
title Antibody Therapies for Large B-Cell Lymphoma
title_full Antibody Therapies for Large B-Cell Lymphoma
title_fullStr Antibody Therapies for Large B-Cell Lymphoma
title_full_unstemmed Antibody Therapies for Large B-Cell Lymphoma
title_short Antibody Therapies for Large B-Cell Lymphoma
title_sort antibody therapies for large b-cell lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141264/
https://www.ncbi.nlm.nih.gov/pubmed/34040344
http://dx.doi.org/10.2147/BTT.S281618
work_keys_str_mv AT novomattia antibodytherapiesforlargebcelllymphoma
AT santambrogioelisa antibodytherapiesforlargebcelllymphoma
AT frascionepiomanliomirko antibodytherapiesforlargebcelllymphoma
AT rotascalabrinidelia antibodytherapiesforlargebcelllymphoma
AT vitoloumberto antibodytherapiesforlargebcelllymphoma